Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Uber

The biotech promises that more collaborations are coming.

Moderna and Uber Teaming Up on Coronavirus Vaccine Awareness Push

Moderna's vaccine delay is hardly fault of its own. The bigger investment picture becomes visible when you ignore the small setbacks and concentrate on the larger factors - in this case, mRNA-1273's superior ease of storage and strong efficacy.

Moderna: Winning The Vaccine Game

BioNTech SE

Pfizer

COVID-19 Vaccine Production to Ramp Up

Moderna (MRNA) plans to initiate clinical studies on new candidates as potential vaccine for seasonal flu, HIV and the Nipah virus.

Moderna (MRNA) Stock Up on Vaccine Pipeline Expansion Plan

The comments highlight what is slowly becoming a consensus among experts: People may need to get regularly vaccinated against Covid-19 for years.

Moderna Executives Say Covid-19 Vaccine Should Offer a Year of Protection

Moderna Inc's (NASDAQ: MRNA) coronavirus vaccine candidate mRNA-1273 gained another regulatory approval Tuesday.  Separately, the company also announced a high-profile executive appointment.

Moderna's Coronavirus Vaccine Secures Swiss Regulatory Approval

Uber and pharmaceutical company Moderna have announced a partnership around COVID-19 vaccination, which will include a number of different initiatives. To start, it's only confirmed component is to provide users with credible, factual information about COVID-19 vaccine safety through Uber's consumer app, but the companies have also discussed additional “options” including building ride scheduling via […]

Uber and Moderna partner on COVID-19 vaccine access and information

Shares of Moderna Inc. were up 0.8% in premarket trading on Tuesday after the company said its COVID-19 vaccine has been authorized in Switzerland. The country has also agreed to purchase 7.5 million doses of the vaccine, with deliveries scheduled to begin next week.

Moderna's COVID-19 vaccine authorized in Switzerland

Uber Technologies Inc. and Moderna Inc. said Tuesday they will collaborate to explore ways to support the uptake of COVID-19 vaccines. The ridesharing and delivery company and the biotech said they will work together to provide "credible information" on vaccine safety through Uber's in-app messaging, and will look to identify opportunities to broaden access to COVID-19 vaccines.

Uber, Moderna to collaborate on supporting COVID-19 vaccine uptake

SAN FRANCISCO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Uber Technologies, Inc. (NYSE: UBER), the world's leading ridesharing and delivery platform, today announced a collaboration to explore ways to help support the uptake of COVID-19 vaccines. Moderna and Uber will work together initially to provide accessible, credible information on vaccine safety through Uber's in-app messaging. The tw

Uber and Moderna Collaborate to Raise Awareness and Increase Access to COVID-19 Vaccines

CAMBRIDGE, Mass.--(BUSINESS WIRE)--José M. Vega, M.D. joins Moderna as Chief Safety Officer.

José M. Vega, M.D. Joins Moderna as Chief Safety Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has authorized the COVID-19 Moderna Vaccine in Switzerland. The authorization is given according to the ordinary approvals procedure and is based on a rolling submission of data and the totality of scientific evidence shared by the Company, including a data analysis from the

Swissmedic Authorizes COVID-19 Vaccine Moderna for Use in Switzerland

Moderna Inc. expects its COVID-19 vaccine to provide immunity to the virus for at least a year, according to remarks made by a company executive at an investor conference on Monday. Shares of Moderna Inc. were up 0.8% in premarket trading on Tuesday.

Moderna exec: Its COVID-19 vaccine likely provides immunity for a year

The U.S. has ordered 200 million doses of the Moderna vaccine, enough to immunize 100 million people.

Moderna Says Its Covid-19 Vaccine Provides One Year's Immunity

It's good news for all Americans, but especially for investors.

Why You'll Love Moderna's Latest COVID Vaccine News

Moderna, Inc. (MRNA) CEO Stéphane Bancel Presents at 39th Annual JPMorgan Virtual Healthcare Conference Transcript

Moderna doesn't expect to have clinical trial data on its coronavirus vaccine in young children until 2022, CEO Stephane Bancel said.

Moderna doesn't expect Covid vaccine data for young children until 2022, CEO says

The stock price of Moderna Inc (NASDAQ: MRNA) increased by 4% as it went from a previous close of $112.75 to $117.26. This is why it happened.

MRNA Stock Price Increased 4%: Why It Happened

Moderna Launches 3 New Vaccine Programs Beyond Coronavirus

AstraZeneca

Johnson & Johnson

This past Friday brought the U.S. its largest single-day amount of Covid-19 cases since the pandemic began in earnest back in March of last year: 310K in a single 24-hour period.

Racing Against Time: Covid-19 vs. Vaccines

Moderna, the biotech company behind one of the two mRNA-based vaccines currently being rolled out globally to stem the tide of COVID-19, has announced that it will purse development programs around three new vaccine candidates in 2021. These include potential vaccines for HIV, seasonal flu and the Nipah virus.

Moderna is developing three new mRNA-based vaccines for seasonal flu, HIV and Nipah virus

Shares of Moderna Inc. were up 1.3% in premarket trading on Monday after the company said it plans to launch new development programs using its mRNA technology that will focus on developing vaccines for seasonal flu, HIV, and the Nipah virus. This follows the success of its mRNA COVID-19 vaccine, which is one of two vaccines to be authorized so far in the U.S. CEO Moderna also said it plans to expand its respiratory syncytial virus to include older adults, and it plans to test different vaccine combinations that fight the flu, COVID-19, RSV, and human metapneumovirus.

Moderna to develop vaccine candidates for seasonal flu, HIV

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

News for Moderna Stock (MRNA)